Cancer Screening and Prevention Research Group

Who we are

The Cancer Screening and Prevention Research Group (CSPRG) is an internationally renowned research group based at Imperial College London. Established in 2008 by the late Professor Wendy Atkin and now headed by Professor Amanda Cross, the group has extensive expertise in conducting clinical trials and includes an experienced team of research scientists, statisticians, clinical trial managers, data analysts and data managers.

What we do

The research focus of the Cancer Screening and Prevention Research Group (CSPRG) is bowel cancer, also known as colorectal cancer. In the UK, over 41,000 people are diagnosed with bowel cancer every year and 16,000 people die from the disease. Through our research we hope to reduce the numbers of people receiving a diagnosis of bowel cancer and dying from this disease. Much of our work focuses on how to help make bowel cancer screening and surveillance programmes more effective and acceptable for participants, and more efficient for the NHS, and other health services internationally.

How we do it

We conduct large-scale studies by either recruiting people from participating healthcare providers or by collating and analysing data collected from UK-based hospitals and other data providers.

How we are funded

We receive funding from the UK Government, through the Department of Health and research councils, as well as charities including Cancer Research UK, 40tude and the Bobby Moore Fund. The Faecal Immunochemical Tests (FIT) for the FIT for Follow-Up study were provided in kind by Eiken Chemical Co. Ltd and Mast Group LtdKeyMed Ltd (now Olympus) provided funding in 1994 for a pilot study in preparation for the UK Flexible Sigmoidoscopy Screening Trial (UKFSST).

Information we may hold about you and your options if you wish to opt out

If you have taken part in a bowel cancer screening programme, gone to your GP with symptoms suggestive of bowel cancer, agreed to participate in one of our studies or had bowel cancer treatment on the NHS, we may retain some information about you. Our Patient Data page provides further details on how we process this data and your options if you wish to opt out.

For researchers โ€“ requesting data

Data used in CSPRG research was collected subject to the informed consent of the participants and / or under section 251 support. Access to the individual-level anonymised data will only be granted in line with the relevant informed consent form or section 251 support, subject to approval by the appropriate research ethics committee, Health Research Authority (HRA) and HRA Confidentiality Advisory Group (HRA-CAG) as required, under a formal data sharing agreement.

To discuss a request for data please contact the CSPRG by completing the contact form with the following information: the proposed study objectives, the data you require and timelines for completion of the research.

โ“#WorldPatientSafetyDay event hosted by @Imperial_PSTRC
๐Ÿ—“๏ธ19 September 2022
๐Ÿ”Ž#patientinvolvement #carerinvolvement

Receive #expert guidance including #PPIE feedback on your #cancerresearch proposal at the next @NCRI_partners guidance meeting Nov 2022. Research areas include #colorectalcancer #cancerscreening #cancerprevention #earlydiagnosis

Apply by 14 Sept๐Ÿ‘‰

WANTED: #ResearchAssociate #HealthEconomist with @NIHR_London_IVD @ImperialSandC @ImperialMed @imperialcollege

Read all about it๐Ÿ‘‡

So, are you joining our exciting programme at #BiCconf22? That's a wrap for the week, don't forget to submit your abstract! We'll be back online Monday, so you might just sneak a last-minute one in over the weekend ๐Ÿ˜‰

Does your research focus on therapeutic #prevention? If so, find out if youโ€™re eligible for our Prevention and Population Research Programme Award. Applications are open until 22 September. Find out more โ€“

Load More